YAP1 and prostate cancer: The upregulation of YAP/TAZ, resulting from the Hippo pathway dysregulation, is a prevalent characteristic observed in numerous types of malignancies, such as non‐small‐cell lung cancer (NSCLC), glioma, pancreatic cancer, sarcoma, colorectal cancer, breast cancer, melanoma, and prostate cancer [13].